US Patent 10,500,162: What Is Claimed, What It Covers, and How It Sits in the Methylphenidate Landscape
US Drug Patent 10,500,162 claims an oral solid, fed-state pharmacokinetic matched ADHD treatment method using a combined immediate-release (IR) and controlled/delayed-release (CR/DR) methylphenidate hydrochloride formulation. The claim scope is defined less by generic “extended-release methylphenidate,” and more by a tight set of PK endpoints (AUC and Cmax windows), duration (16 hours), and dissolution constraints that run through both method and bead-architecture dependent claims.
What is the core independent claim scope (Claims 1 and 19)?
Claim 1 (method of treating ADHD) and Claim 19 (same, but with Cmax endpoints instead of AUC endpoints) are the two independent anchors.
A. Dose and formulation architecture
Both independent claims require:
- Oral solid pharmaceutical composition
- Contains:
- Immediate release methylphenidate HCl component
- Controlled/delayed release methylphenidate HCl component
- Together provide 25, 35, 45, 55, 70, 85, or 100 mg methylphenidate HCl.
B. “Fed state” PK endpoint constraints
C. Duration and exposure-to-therapy linkage
Both independent claims require:
- Efficacious treatment of ADHD for 16 hours after a single oral administration.
D. In vitro dissolution profile (USP paddle method)
Both independent claims lock the formulation to a specific dissolution pattern tested by:
- USP paddle method, 100 rpm, 37°C
- Medium sequence:
- 2 hours in 900 mL simulated gastric fluid
- 4 hours in 900 mL phosphate buffer pH 6.0
- From 7th hour onward: 900 mL phosphate buffer pH 7.4
- Dissolution acceptance:
- 1 hr: NLT 15%
- 4 hr: 18%–38%
- 8 hr: 35%–55%
- 12 hr: 68%–98%
- 16 hr: NLT 68%
- Uses the language: “USP <711> Acceptance Table 2.”
E. Feed-state Tmax constraints (dependent)
- Claim 2 / 20 add fed-state:
- Tmax0-4 about 3 hours
- Tmax8-16 about 13.5 hours
Interpretation for enforcement: Claim 10.5 of “what matters” is not the general concept of biphasic methylphenidate. It is compliance with explicit dissolution curves plus explicit fed-state PK parameter windows, with the “16 hours” treatment claim tethered to that PK behavior.
What dependent claims narrow the product architecture (Claims 3-18 and 21-28)?
Dependent claims convert the broad IR+CR/DR concept into a specific bead-based multi-layer structure and specify coating materials and weight percentages.
A. Bead-based dual-component placement
- Claim 3 / 21: CR/DR and IR are provided via a plurality of coated beads.
- Claim 4 / 22: each bead has a portion of CR/DR and a portion of IR.
- Claim 5 / 23: bead core has a first amount corresponding to CR/DR.
- Claim 6 / 24: core is:
- granule coated with first amount or
- granule substrate in admixture with first amount.
- Claim 7 / 25: core comprises granule coated with first amount.
B. Inner controlled release + outer delayed release on the first portion
- Claim 8 / 26: first amount coating includes:
- inner controlled release coating
- outer delayed release coating over inner controlled release coating
- Claim 9 / 27: second amount (IR portion) is coated over the outer delayed release coating.
This layering matters because it fixes how IR is positioned relative to the CR/DR shell. It reduces design-around latitude versus formulations where IR is physically separated into distinct bead populations or where the CR/DR layers differ in order.
C. Weight fraction ranges of CR/DR vs IR
- Claim 10 / 28: CR/DR component is about 70 wt% to about 99 wt% of total dose (25-100 mg range).
- Claim 11: CR/DR is about 78 wt% to about 82 wt%.
- Claim 12: CR/DR is about 80 wt%; IR provides about 20 wt%.
So the claim set spans:
- a broad band (70-99%) and
- a tight engineered band centered at 80/20 (CR/DR/IR), with multiple dependents.
D. Granule substrate menu (Claim 13)
Granule substrate is selected from:
- sugar sphere
- microcrystalline cellulose granule
- silica granule
- starch granule
- lactose granule
- calcium carbonate granule
- mannitol-polyvinylpyrrolidone granule
E. Coating weight % ranges
- Claim 14: inner controlled release coating 3%–16% by weight of each bead; outer delayed release coating 3%–20% by weight.
- Claim 15: narrower:
- inner controlled release: 10.0%–10.7%
- outer delayed release: 15%–16%
These narrow bands are a practical target for product match testing.
F. Polymer identities (Claims 16-18)
-
Claim 16: inner controlled release coating is selected from:
- ethylcellulose polymer
- cellulose ether
- polyethylene oxide
- polyvinyl alcohol derivative
- methacrylic acid copolymer
- polyethylene glycol
- polyglycolic acid
- polylactic acid
- polycaprolactone
- poly(n-hydroxybutyrate)
- polyamino acid
- poly(amide-enamine)
- polyester
- EVA
- PVP
- PAA
- PMAA
- mixtures
-
Claim 17: inner controlled release comprises ammonio methacrylate copolymer, Type B USP/NF.
-
Claim 18: outer delayed release comprises poly(methyl acrylate-co-methyl methacrylate-co-methacrylic acid) 7:3:1.
Dependent claims 17-18 are “material identity locks” that can matter in litigation if accused products share the same architecture but use a different polymer system.
What does the scope imply about enforceable product features?
From the claim set, the enforceable feature checklist is:
- Oral solid IR/CR/DR methylphenidate HCl in specified dose sizes (25-100 mg).
- Fed-state PK matching:
- Claim 1: AUC0-4, AUC8-12, AUC12-16 with stated mean ± SD at 100 mg and dose-proportional scaling for other listed doses.
- Claim 19: fed-state Cmax0-4 and Cmax8-16 similarly constrained.
- Therapeutic duration: “16 hours” after single administration.
- Dissolution profile: USP paddle, USP <711> Acceptance Table 2, medium switching scheme, and exact percent dissolved bands at 1/4/8/12/16 hours.
- Bead architecture: coated beads with CR/DR and IR portions in each bead.
- Layer order: inner controlled release then outer delayed release, with IR coated over outer delayed release.
- Composition ratio: CR/DR fraction ranges from 70-99% (and specifically 78-82%, or about 80%).
- Coating loads and materials: bead coating weight ranges plus polymer identity dependents.
A design-around that avoids one constraint can still fall within broader dependent claims unless it changes the architecture beyond those dependents. The strongest “all-in” infringement path is a product whose dissolution and fed-state PK match, and whose bead architecture matches the layer order and weight fraction.
How does US 10,500,162 fit in the methylphenidate patent landscape?
Landscape structure: two claim families
Without relying on external prosecution histories, the claim language itself indicates US 10,500,162 sits at the intersection of:
- extended-release methylphenidate formulations with biphasic release behavior, and
- bead-based multilayer technology tied to specific dissolution and fed-state PK targets.
This is consistent with a landscape where brands and generics compete via:
- IR/ER or multipulse release technologies,
- dissolution spec and PK matching strategies for generics,
- bead/layer-specific formulations for non-infringement or design changes.
Where the “scope pressure points” are
The patent’s strongest differentiators, for landscape mapping, are the explicit testable constraints:
A. Dissolution and media sequence (USP paddle, pH transitions)
- The test medium order and phosphate buffer pH sequence define a reproducible release behavior target. Competitors that use different excipients or coat load profiles may still pass general extended-release specs but fail the exact banding.
B. Fed-state PK parameter windows
- Many methylphenidate products claim “extended duration,” but this patent quantifies AUC ranges (Claim 1) and Cmax windows (Claim 19). Those numeric constraints can narrow the overlap between formulation families.
C. Layer order inside beads
- The claim fixes a three-layer relationship: inner controlled release, then outer delayed release, with IR coated over outer delayed release. Competing bead designs that reverse layer placement or isolate IR and ER into different bead populations move away from these dependents.
Competitive positioning by likely technology class
Based on claim wording, the patent covers formulations that resemble a multi-layer coated bead platform for biphasic release, with:
- a controlled/ delayed release shell carrying the majority of methylphenidate, and
- an IR overcoat providing earlier exposure.
In market terms, this claim set is positioned to overlap with:
- long-acting methylphenidate products that rely on multilayer pellets/beads, and
- follow-on products attempting to match brand-like fed-state exposure and dissolution.
Practical claim construction: what is “required” vs “optional” in infringement analysis
Required elements (cannot be bypassed)
- Oral solid formulation comprising both IR and controlled/delayed release methylphenidate HCl components.
- Dose range: 25, 35, 45, 55, 70, 85, or 100 mg.
- Fed-state PK endpoint match (AUCs in Claim 1; Cmax windows in Claim 19).
- 16-hour ADHD treatment efficacy after a single administration.
- Specific dissolution profile under the defined USP paddle protocol.
Optional/narrowing elements (only matter if relevant claim is asserted)
- Bead structure and layer order (Claims 3-9, 21-27).
- Specific CR/DR weight fraction bands (Claims 10-12, 28).
- Specific coating loads and polymer identities (Claims 14-18).
Key Takeaways
- US 10,500,162 is an “IR + CR/DR multilayer bead” patent with numeric fed-state PK and dissolution locks.
- The independent claims are Claim 1 (fed-state AUC0-4/AUC8-12/AUC12-16) and Claim 19 (fed-state Cmax0-4/Cmax8-16), both tied to 16-hour ADHD efficacy and a USP paddle dissolution profile with pH transitions.
- Dependent claims narrow scope to a specific bead architecture: CR/DR in the bead core with inner controlled release + outer delayed release, then IR coated over the outer delayed release.
- The claim set further narrows by CR/DR wt% (70-99%, centered around ~80%), coating loads, and polymer identity dependents (including ammonio methacrylate Type B and a 7:3:1 poly(methyl acrylate-co-methyl methacrylate-co-methacrylic acid) copolymer).
FAQs
1) Does US 10,500,162 cover any extended-release methylphenidate with a 16-hour duration?
No. It requires specific fed-state PK endpoints (AUC or Cmax windows depending on the independent claim) plus the defined dissolution profile under USP paddle conditions.
2) What is the difference between Claim 1 and Claim 19?
Claim 1 uses fed-state AUC0-4, AUC8-12, and AUC12-16 targets; Claim 19 uses fed-state Cmax0-4 and Cmax8-16 targets, with both tied to 16-hour efficacy and the same dissolution scheme.
3) Are the bead-layer claims mandatory for infringement of the independent claims?
The bead-layer structure is not required for Claim 1 or Claim 19 themselves, but it is required for the dependent claims that recite coated beads, core structure, and coating order.
4) Which claim terms most constrain formulation design-around?
The tight combination of (i) USP paddle dissolution bands with pH transitions, (ii) fed-state PK numeric windows, and (iii) IR overcoat placed over an outer delayed-release layer on the same bead.
5) What do the polymer-specific dependents add to the landscape?
Claims 17-18 narrow to defined polymer identities for inner and outer coatings, which can limit a formulation that otherwise matches dissolution and PK but uses different coat chemistry.
References
[1] US 10,500,162, Claims 1-28 (provided claim text).
